Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Lpath Inc.

Market Cap as of 6/12/2015

Market Cap as of 7/03/2014

$61,887,726

Market Cap as of 07/02/2013

$61,177,643

Market Cap as of 06/26/2012

$58,239,548

Market Cap as of 01/04/2012

$71,438,550

Market Cap as of 06/20/2011

$62,277,550

Market Cap as of 01/06/2011

$45,357,620

Exchange and Ticker Symbol

OTC BB: LPTN

Fields of Research

Focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States

Major Products

iSONEP (the ocular formulation of humanized Sphingomab)
ASONEP (the systemic formulation of humanized Sphingomab)
Lpathomab (a monoclonal antibody against lysophosphatidic acid)

Stocks

Company Trade Data

Stock Symbol Close Change Volume 52-Week
Chg %Chg High Low
LPTN
0.22
  -0.01  
- 4.35%
303,785,000
3.75
0.18

Executives

Scott Pancoast

  • Chief Executive Officer
  • President

Related News

Articles

Lpath reports interim results in cancer drug trial

Lpath Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.

Lpath kidney drug missed Phase 2 goal

San Diego biotech Lpath Inc. (Nasdaq: LPTN) reported that its Phase 2a study of Asonep for the treatment of kidney cancer did not lead to statistically significant progression-free survival in patients with advanced renal cell carcinoma.

Similar Companies

Biological Product (except Diagnostic) Manufacturing325414
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES2836